Cryolife Inc (NYSE:CRY) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Cryolife Inc (NYSE:CRY) have been assigned a consensus rating of “Buy” from the six brokerages that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $33.50.

Several analysts have recently issued reports on the company. Needham & Company LLC reiterated a “hold” rating on shares of Cryolife in a research note on Sunday, May 12th. Zacks Investment Research upgraded Cryolife from a “sell” rating to a “hold” rating in a research note on Tuesday, April 23rd. TheStreet cut Cryolife from a “b-” rating to a “c+” rating in a research note on Wednesday, May 22nd. Canaccord Genuity set a $35.00 price objective on Cryolife and gave the company a “buy” rating in a research note on Wednesday, July 31st. Finally, ValuEngine cut Cryolife from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 15th.

In other Cryolife news, Director Ronald D. Mccall sold 3,700 shares of the firm’s stock in a transaction on Thursday, May 23rd. The stock was sold at an average price of $28.74, for a total value of $106,338.00. Following the sale, the director now directly owns 139,162 shares in the company, valued at $3,999,515.88. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Scott B. Capps sold 2,000 shares of the firm’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $28.55, for a total value of $57,100.00. Following the completion of the sale, the vice president now owns 141,079 shares in the company, valued at $4,027,805.45. The disclosure for this sale can be found here. 4.40% of the stock is currently owned by company insiders.



Institutional investors have recently bought and sold shares of the business. Rhumbline Advisers raised its stake in shares of Cryolife by 0.6% in the 1st quarter. Rhumbline Advisers now owns 100,456 shares of the medical equipment provider’s stock valued at $2,930,000 after purchasing an additional 612 shares in the last quarter. Hodges Capital Management Inc. acquired a new stake in shares of Cryolife during the 1st quarter valued at approximately $3,779,000. SG Capital Management LLC acquired a new stake in shares of Cryolife during the 1st quarter valued at approximately $2,227,000. Bank of America Corp DE lifted its position in shares of Cryolife by 11.3% during the 4th quarter. Bank of America Corp DE now owns 123,223 shares of the medical equipment provider’s stock valued at $3,497,000 after acquiring an additional 12,465 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Cryolife by 11.3% during the 4th quarter. Geode Capital Management LLC now owns 366,746 shares of the medical equipment provider’s stock valued at $10,408,000 after acquiring an additional 37,096 shares during the period. Institutional investors own 70.63% of the company’s stock.

NYSE:CRY traded up $0.23 during trading hours on Friday, reaching $26.21. 9,302 shares of the stock were exchanged, compared to its average volume of 176,819. The company has a quick ratio of 3.82, a current ratio of 5.03 and a debt-to-equity ratio of 0.83. The business has a 50-day moving average of $29.17 and a two-hundred day moving average of $29.28. Cryolife has a twelve month low of $23.99 and a twelve month high of $36.05. The company has a market capitalization of $978.64 million, a price-to-earnings ratio of 100.42 and a beta of 0.62.

Cryolife (NYSE:CRY) last released its quarterly earnings results on Tuesday, July 30th. The medical equipment provider reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.03. Cryolife had a return on equity of 3.85% and a net margin of 0.87%. The company had revenue of $71.14 million for the quarter, compared to analysts’ expectations of $70.79 million. During the same period in the prior year, the firm earned $0.10 earnings per share. The firm’s revenue was up 3.9% compared to the same quarter last year. On average, research analysts forecast that Cryolife will post 0.29 EPS for the current fiscal year.

About Cryolife

CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.

Further Reading: Trade War

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.